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In vivo effect of 1,25-dihydroxyvitamin D3 on phagocyte function in
hemodialysis patients. 1,25-dihydroxyvitamin D3 [l,25(OH)2D31 has
been shown to modulate the immune function of monocytes and
macrophages. Patients with end-stage renal disease (ESRD) on chronic
hemodialysis treatment usually present a deficiency of this active form
of vitamin D3. The aim of this study was to investigate the effect of
1 ,25(OH)2D3 replacement therapy on phagocytosis, bactericidal capac-
ity, and oxidative metabolism of peripheral blood polymorphonuclear
leukocytes (PMNL) and monocytes (MN) in chronic hemodialysis
patients. Phagocyte function tests were performed before and after four
weeks of an oral replacement therapy with 0.5 .tg/day of I ,25(OH)2D3
(Rocaltrol). The superoxide (02) generation of monocytes, measured
by cytochrome c reduction and lucigenin-enhanced chemiluminescence
(CL) from patients receiving hemodialysis treatment was significantly
diminished compared to healthy controls. After the replacement ther-
apy with l,25(OH)2D3 the O2 production showed a significant im-
provement, resulting in an increased cytochrome c reduction and
lucigenin-CL response. The bactericidal capacity of MN was also
impaired and exhibited a significant enhancement of their killing activity
after the administration of l,25(OH)2D3. On the other hand, the
luminol-enhanced CL, which reflects the myeloperoxidase-dependent
oxidative metabolism, and the phagocytic ability of MN was not
affected by the hormone. The function of polymorphonuclear leuko-
cytes (PMNL) from hemodialysis patients showed no impairment in the
state of! ,25(OH)2D3 deficiency and the replacement of the hormone did
not enhance their function. These results suggest that the deficiency of
l,25(OH)2D3 in patients with ESRD on chronic hemodialysis treatment
may be responsible for an impaired monocyte function, which could be
improved by an in vivo replacement of the hormone.
Infection is a frequent complication and a major cause of
morbidity and mortality in patients with end-stage renal disease
(ESRD) who are on regular dialysis treatment [1, 2]. Abnormal-
ities of the immune system could partly contribute to an
increased susceptibility for bacterial infections. Several alter-
ations of leukocyte function in patients with ESRD have been
demonstrated, including both impaired neutrophil and mono-
cyte function [3]. A decreased chemotaxis and reduced produc-
tion of reactive oxygen metabolites during the "respiratory
burst" of polymorphonuclear leukocytes and monocytes have
been reported [4, 5]. These functions seem to decrease further
with duration of dialysis treatment [6].
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The secosteroid hormone 1 ,25-dihydroxyvitamin D3
[1,25(OH)2D3] is the active metabolite of vitamin D3 and plays
an important role in calcium hemostasis and skeletal metabo-
lism. Recently it has been shown that l,25(OH)2D3 exhibits
immunodulatory activities, interacting with lymphocytes and
mononuclear phagocytes [7]. Peripheral blood monocytes and
tissue macrophages show an enhancement of the oxidative
metabolism after in vitro incubation with 1,25(OH)2D3 [8—11].
In addition, 1,25(OH)2D3 is capable of inducing monocytic
differentiation in various human [121 and murine [13] leukemic
cell lineages. Abnormal macrophage function with a decreased
chemotaxis and phagocytosis has been demonstrated in vitamin
D-deficient mice and could be corrected after in vitro and in
vivo replacement of the hormone [14]. Similar phagocyte alter-
ations have been shown in children with rickets [15]. Further-
more, an improvement of a diminished leukocyte chemotaxis
has been reported in patients with ESRD on hemodialysis
treatment after in vitro and in vivo administration of
1,25(OH)2D3 [16].
Patients with ESRD usually present a deficiency of active
1 ,25(OH)2D3 due to the loss of renoparenchymal function. The
present study was undertaken to determine the effect of
1 ,25(OH)2D3 on phagocytosis and oxidative metabolism of
polymorphonuclear leukocytes (PMNL) and peripheral blood
monocytes (MN) after in vivo replacement therapy with oral
l,25(OH)2D3 (Rocaltrol®) in patients with ESRD on regular
hemodialysis treatment.
Methods
Patients
Twelve patients (7 d', 59; mean age 56.4 13.1 years) with
chronic renal failure on stable hemodialysis (3 times per week
for 4 hours) who were not receiving any form of vitamin D
therapy were investigated. The underlying kidney diseases
were chronic glomerulonephritis (5), membranous nephropathy
(1), tubular interstitial nephritis (2), polycystic kidney disease
(2), reflux (I), and analgetic nephropathy (1).
Patients with diabetic nephropathy or with a medication of
steroids, NSAID or immunosuppressive drugs were excluded
from the study. Furthermore, patients with clinical evidence of
infection and operations in the last four weeks prior to the
entrance into the study were also excluded.
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The patients received 0.5 zg 1 ,25-dihydroxyvitamin D3 (Ro-
caltrol®) per os daily for four weeks. Calcium containing
phosphate binders were replaced where necessary by alumin-
ium hydroxyde during the study to avoid hypercalcemia. Phago-
cyte function tests were performed in vitro before and after the
treatment. Serum levels of I ,25(OH)2D3 and intact parathyroid
hormone (iPTH) were determined in the Bioscienta Laborato-
ries (Ingeiheim, Germany).
Controls
Twelve sex- and age-matched healthy adult volunteers with
normal renal function and without signs of infection in the last
four weeks served as controls.
Blood collection and preparation of leukocytes
Venous blood was collected into heparinized (10 U/mI)
syringes containing 6% dextran in 0,9% saline (wt/vol). In
patients on hemodialysis blood was obtained prior to dialysis.
After sedimentation at room temperature for 45 minutes, the
leukocyte-rich plasma was centrifuged at 350 g for 10 minutes
(+4°C), and the pellet was resuspended in 15 ml Hanks bal-
anced salt solution containing 0.1% gelatin (GHBSS). Polymor-
phonuclear leukocytes and mononuclear cells were separated
by gradient density centrifugation at 350 g for 20 minutes at
+4°C over Ficoll-Paque (Pharmacia, Uppsala, Sweden) by a
method described elsewhere [171. The PMNL fraction was
rendered erythrocyte free by hypotonic lysis with 0.2% sodium
chloride for one minute, and isotonicity was restored with an
equal volume of 1.6% sodium chloride. After washing the
polymorphonuclear and mononuclear cells twice with GHBSS
cells were counted in a automatic cell counter (Sysmex,
K-bOO, ba, Kobe, Japan). Subsequently, differential cell
counts were performed using May-Grunwald-Giemsa staining
and showed 92 2% PMNL. The mononuclear cell fraction
contained 35 5% monocytes (MN), when stained for the
presence of unspecific esterase (LeucoGnost® EST-Set, Merck,
Darmstadt, Germany). Cell viability was evaluated by Trypan
blue exclusion and always exceeded 95%. Finally, cells were
resuspended in GHBSS at a concentration of 5 X 106 PMNL or
MN/mi.
Superoxide anion measurement
The generation of superoxide anions by phagocytes was
measured by assessment of superoxide-dismutase (SOD)-in-
hibitable cytochrome c reduction according to the method of
Babior, Kipnes and Curnutte [18].
In brief, two pairs of polypropylene tubes containing either
PMNL or MN (5 x l05/ml), ferricytochrome c (type VI, Sigma;
90 /LM) and PMA (50 ng/ml) were placed in a shaking incubator
for 10 minutes at 37°C in the presence and absence of SOD (100
jsg/ml; Sigma) in a final volume of 1 ml. Prior to the addition of
PMA, reaction mixtures were preincubated for five minutes at
37°C in a water bath and at the end of the incubation period
superoxide production was terminated by placing the tubes on
ice. Leukocytes were removed by centrifugation at 4°C (350 x
g, 10 mm). The cell-free supernatants were used for determina-
tion of cytochrome c reduction by measuring the absorbance at
550 nm on a spectrophotometer (DU-62, Beckman Instruments,
Munich, Germany). The probes containing SOD were em-
ployed as reference. Values from duplicate samples without
SOD were averaged and results were converted in nanomoles of
cytochrome c reduced per 106 cells per minute by using
extinction coefficient E550 nm = 2.1 x lO M1 cm'.
Chemiluminescence (CL) assay
To assess the respiratory burst activity of PMNL and MN
two CL assay systems were used [19]. Lucigenin was used as a
chemilumigenic probe to detect superoxide production, and
luminol was used to detect oxygen metabolites arising from
myeloperoxidase activity. CL mixtures in transparent plastic
scintillation vials contained 500 d of PMNL or MN (5 x l05/ml
in GHBSS), 50 d of either 2.5 M luminol (5-amino-2,3-
dihydro- 1 ,4-phthalazine-dione; Sigma) or 250 tM lucigenin
(l0,l0-dimethyl-9,9' biacridinium-dinitrate, Sigma) and 50 d
phorbol myristate acetate (PMA, 50 ng/ml; Sigma) as the CL
stimulus. Prior to the addition of the stimulus (PMA) all samples
were preincubated for six minutes in the measuring chamber at
37°C and background CL (0.2 to 1.6 x l0/i0 cells) was
recorded. After the addition of PMA counts were obtained
every two minutes for 30 minutes by using an automatic
luminescence analyzer (LB 950, Berthold, Wildbad, Germany).
CL results were expressed as the number of peak cpm per
cells.
Bacterial strain and culture conditions
Staphylococcus aureus Cowan I, a protein A-rich strain, was
used in this study (provided by Prof. Verhoef and Dr. Ver-
brugh, University of Utrecht, Department of Microbiology, The
Netherlands). For each experiment overnight cultures of bac-
teria were used, grown in 5 ml Muller-Hinton broth (Heipha,
Heidelberg, Germany) at 37°C in a shaking incubator. After
washing three times with phosphate-buffered saline (PBS, pH
7.4), bacteria were resuspended in GHBSS to a concentration
of 5 x 108 colony-forming units (cfu/ml) using optical density
measurement at 560 nm. The results were confirmed by plate
colony counts. For the phagocytosis assay, the bacteria were
radiolabeled by addition of 20 tCi [3H] adenine into the
overnight culture.
Opsonins and opsinisation procedure
Human pooled serum (HPS) was obtained from 10 healthy
donors and aliquots were stored at —70°C until use. Just prior to
the use, serum was diluted to 10% in GHBSS. Bacterial
suspension (0.1 ml containing 5 x 108 cfu/ml) was mixed with
0.9 ml of the 10% HPS and incubated for 30 minutes at 37°C.
The suspension was centrifuged and the bacterial pellet resus-
pended in 1 ml GHBSS and kept on ice until use (preopsonized
bacteria).
Bacterial killing assay
The bactericidal capacity of PMNL and MN was determined
in an assay modified from Quie et al [20]. Quadruplicate tubes
with 100 d preopsonized bacteria (5 x io cfu/ml) and 100 sl
PMNL or MN (5 x 106/ml) were constituted. To one pair of
samples 2.5 ml ice-cold sterile water was added immediately
after the mixtures were composed (zero-time). The other pair
was placed in a shaking incubator at 37°C and stopped after 60
minutes by adding ice-cold water as described above.
Subsequently, 200-fold dilutions in sterile Aqua dest. were
made and duplicate 100 1.d samples were striked out on agar
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Table 1. Blood biochemistry before and after 1 ,25(OH)2D3
replacement therapy from patients with chronic dialysis treatment
Patients on chronic dialysis
treatment
Before After
1 ,25(OH)2D3 1 ,25(OH)2D3
(Normal values) Controls therapy therapy
l,25(OH)2D3 36.7 18.5 8.5 2.6e 24.3 14.5"
(19—67 pg/mi)
Intact PTH 2.5 1.2 23.8 29.8" 11.3 l6.8'
(1.0—5.1 pmol/liter)
Calcium 2.29 0.08 2.34 0.16 2.55 0.22°
(1.90—2.60 mmol/
liter)
Phosphate 1.00 0.16 1.66 0.50 1.89 Ø55a
(0.68—1.68 mmol/
liter)
Alkaline phosphatase 94.6 17.4 104.5 27.3 108.0 33.6
(60—200 U/liter)
Serum creatinine 0.85 0.17 9.7 2.5 9.8 2.7
(—1.4 mg/dl)
Urea mgldl 32.1 8.2 148.3 345e 154.7 40.7
Hemoglobin gI/iter 14.3 1.2 9.5 1.4° 9.3 1.6
Total WBC count 6.2 1.7 6.6 1.7 6.2 1.2
(x103/j.d)
Data are mean SD
a p < 0.05 vs. pretreatment with 1,25(OH)2D3
b P < 0.001 vs. pretreatment with l,25(OH)2D3
P < 0.0005 vs. pretreatment with 1,25(OH)2D3;
vs. controls
P <0.0001 vs. controls
plates (Colombia blood agar, Heipha, Heidelberg, Germany).
After incubation for 18 hours at 37°C colonies were counted and
results are expressed as the percentage of colonies killed after
60 minutes of incubation (percentage decrease in the number of
cfu after the incubation period).
Phagocytosis assay
The uptake of preopsonized radiolabeled bacteria by phago-
cytic cells was determined in an assay described previously by
Peterson eta! [21]. In duplicate samples, 100 d of preposonized
bacteria (5 x io cfu/ml) were mixed with 100 l of PMNL or
MN (5 x 106/ml) in polypropylene vials (Wheaton omni-vials,
Zinsser Analytic, Frankfurt, Germany) and incubated for 60
minutes at 37°C in a shaking incubator. The final bacteria-to-
phagocyte ratio was 10:1. Phagocytosis was stopped by adding
3 ml of ice-cold GHBSS to the mixture. Subsequently the
nonphagocyte-associated bacteria were removed by three times
washing with GHBSS and differential centrifugation (160 x g,
4°C, 5 mm) [221. The final cell pellet was solved in 2.5 ml of
scintillation liquid (Xylol containing Quickszint 212, Zinsser
Analytic, Frankfurt, Germany) and phagocyte-associated radio-
activity was determined in a liquid scintillation counter (Beck-
man Instruments). Phagocytosis was expressed as the percent-
age of uptake of total added radioactivity, based on the average
of two separate vials containing radiolabeled bacteria alone.
Statistical evaluation
Evaluation of the results was done by using Student's t-test
for paired and unpaired data, respectively. Levels of P 0.05
were regarded as statistically significant. Data were presented
as mean SD.
Table 2. Effect of 1 ,25(OH)2D3 therapy on superoxide (02)
production of polymorphonuclear leukocytes (PMNL) and monocytes
(MN) from patients with chronic dialysis treatment
Cells
nmol cytochrome c reduction/b" cells/mm
Controls
Patients on chronic dialysis
treatment
Before After
I ,25(OH)2D3 1 ,25(OH)2D3
therapy therapy
PMNL
MN
15.49 6.68
10.10 2.98
13.08 2.56" 14.66 4.26°
6.72 2.72" 8.96 2.42"
Data are mean SD.
a NS (P> 0.05) vs. controls
b P = 0.012 vs. controls
NS (P> 0.05) vs. pretreatment with l,25(OH)2D3d P = 0.026 vs. pretreatment with l,25(OH)2D3
Results
Twelve patients with end-stage renal disease (ESRD) who
were on regular hemodialysis treatment, and not receiving any
form of vitamin D supplementation were included in the study.
Polymorphonuclear (PMNL) and monocyte (MN) function tests
were performed before and after a four week course of treat-
ment with 0.5 g 1,25-dihydroxyvitamin D3 (Rocaltrol®) daily
per os. Laboratory values obtained before and after the treat-
ment are summarized in Table 1. Blood levels of I ,25(OH)2D3
increased significantly after the replacement therapy with Ro-
caltrol® and reached normal values after the administration, but
were still lower than those of controls. The blood calcium and
phosphate concentration showed a significant increase,
whereas the intact parathormone (iPTH) significantly de-
creased. Other laboratory parameters remained unchanged
during the treatment course.
Sup eroxide production
The results of the superoxide (02) production of PMNL and
MN in response to stimulation with PMA, measured by cy-
tochrome c reduction, are shown in Table 2. The generation of
superoxide by monocytes from patients receiving dialysis was
significantly diminished compared to healthy controls (6.72
2.72 vs. 10.10 2.98 nmol/lO" cells/mm; P = 0.012). After the
1 ,25(OH)2D3 therapy the 02 production by MN showed a
significant increase in the patients, nearly reaching the levels of
controls (8.96 2.42 nmol/10" cells/mm; P = 0.026). No
significant correlation was seen between increase of cy-
tochrome c reduction and serum levels of PTH (r = —0.542, P
= 0.106), calcium (r = —0.279, P = 0.435) and phosphate (r =
—0.093, P = 0.799).
The generation of °2 by PMNL did not exhibit a significant
increase after treatment with 1,25(OH)2D3 (14.66 4.26 vs.
13.08 2.56, P = 0.236).
Chemiluminescence
MN from patients on dialysis treatment exhibited a signifi-
cantly reduced lucigenin-enhanced CL response compared to
that of healthy controls (146.3 x l0 59.7 x iO cpm/104 cells
vs. 209.2 x i0 72.0 x iO cpm/104 cells, P = 0.04). Their CL
response showed a significant improvement after the therapy
with l,25(OH)2D3 (182.2 x i03 44.5 x i03 cpm!104 cells, P =
xa
-J0
a,0
Fig. 1. Lucigenin-enhanced chemiluminescence (CL) of PMA-stimu-
lated polymorphonuclear leukocytes (PMNL) and monocytes (MN)
from patients with chronic dialysis treatment before () andafter ()
replacement therapy with 1,25(OH)2D3 compared to healthy controls(•). Data are mean SD; * P = 0.04, ** P = 0.007.
0.007; Fig. 1). There was no significant correlation between the
increased lucigenin-CL and serum levels of PTH (r =
—0.257, P
= 0.474), calcium (r = —0.546, P 0.103) and phosphate (r
—0.079, P = 0.828).
The lucigenin-CL generation of PMNL was slightly, but not
significantly reduced (141.3 x jo3 44.6 x l0 cpm/104 cells vs.
173.4 x l0 54.0 x l0 cpm/104 cells; P = 0.127) and
remained unchanged after l,25(OH)2D3 supplementation (147.3
x l0 35.2 x l0 cpmIlO4 cells; P = 0.524).
The luminol-enhanced CL produced by PMNL and MN from
patients after stimulation with PMA is shown in Figure 2. The
peak CL response of PMNL and MN from patients receiving
dialysis treatment did not differ significantly from those of
controls (PMNL: 341.2 x i0 121.2 x l0 cpm!104 cells vs.
378.6 x i0 64.9 x l0 cpm/104 cells, P = 0.356; MN: 228.5
89.2 x lQ cells/104 cells vs. 278.4 73,0 x io cpm/l04 cells,
P = 0.164). Replacement therapy with 1,25(OH)2D3 did not
affect the luminol-enhanced CL from both PMNL and MN.
Bacterial killing
The killing capacity of S. aureus by MN from patients on
dialysis was significantly reduced compared to that of healthy
controls (71.2 14.3% vs. 84.3 6.7%, P = 0.011) and showed
a significant improvement after I ,25(OH)2D3 therapy (71.2
14.3% to 83.5 6.9%; P = 0.019). No significant correlation
was seen between increase of killing capacity of MN and serum
levels of PTH (r =
—0.144, P = 0.673), calcium (r = —0.158, P
= 0.643) and phosphate (r —0.418, P = 0.201).
The ability of PMNL to kill S. aureus did not vary from that
of controls and remained unchanged under treatment with
1,25(OH)2D3 (Fig. 3).
Phagocytosis
The phagocytic ability (uptake of preopsonized S. aureus) of
PMNL and MN from patients receiving chronic dialysis was
similar to that of healthy controls and was not affected by
l,25(OH)2D3 replacement therapy (Table 3).
Discussion
Recently, it has been demonstrated that the secosteroid
hormone 1 ,25(OH)2D3 is not only important for calcium hemo-
stasis and bone metabolism, but also has immunodulatory
properties 17]. It is well known that 1,25(OH)2D3 induces the in
vitro differentiation of leukemic and normal myeloid stem cells,
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Fig. 2. Luminol-enhanced chemiluminescence (CL) of PMA-stimu-
lated polymorphonuclear leukocytes (PMNL) and monocytes (MN)
from patients with chronic dialysis treatment before () and after ()
replacement therapy with 1 ,25(OH)2D3 compared to healthy controls(. Data are mean SD.
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as well as that of peripheral blood monocytes toward macro-
phages [12, 23]. Furthermore, the hormone enhances the oxi-
dative metabolism of peripheral blood monocytes (MN) and
peritoneal macrophages (PMØ) in vitro, resulting in an in-
creased production of hydrogen peroxide and superoxide [8—11]
and an augmented killing of mycobacteria [241. The action of
1 ,25(OH)2D3 is mediated by a specific receptor on monocytes
[25] and its expression increased after administration of
l,25(OH)2D3 [26]. Consistent with these observations are the
findings of an abnormal phagocyte function in vitamin D-defi-
cient mice [14] and in humans with rickets [15].
Patients with end-stage renal disease (ESRD) on chronic
dialysis treatment usually present a deficiency of 1 ,25(OH)2D3,
due to the loss of renoparenchymal function and inhibition of
la-hydroxylase by hyperphosphatemia. Several alterations of
leukocyte function have been demonstrated in these patients,
including impaired phagocyte function [3]. Venezio et al [16]
could demonstrate an impaired chemotaxis of PMNL and MN
from patients on hemodialysis, which improved after therapy
with 1,25(OH)2D3.
The present study demonstrates that patients with ESRD on
regular hemodialysis treatment showed markedly reduced se-
rum levels of 1,25(OH)2D3, and that their peripheral blood MN
exhibited a diminished oxidative metabolism and killing activ-
Table 3. Phagocytosis of preopsonized S. aureus by
polymorphonuclear leukocytes (PMNL) and monocytes (MN) from
patients receiving chronic dialysis treatment under 1 ,25(OH)2D3
therapy
Cells
% Phagocytosis 60 mm
Controls
Patients on chronic dialysis
treatment
Before After
1 ,25(OH)2D3 I ,25(OH)2D3
therapy therapy
PMNL
MN
35.9 5.5
37.4 6.4
36.9 5.2 36.6 104b
38.9 7.Oa 40.1 9•7b
Data are mean SD.
NS (P> 0.05) vs. controlsb NS (P> 0.05) vs. pretreatment with 1,25(OH)2D3
ity. After the administration of Rocaltrol® normal serum values
of l,25(OH)2D3 were obtained, which, however, were still
lower than those of healthy controls. Furthermore, the MN
from patients with ESRD on hemodialysis showed a significant
improvement of their oxidative metabolism and bactericidal
capacity after the in vivo replacement of 1,25(OH)2D3.
The PMA-stimulated superoxide (02) generation of MN,
measured by cytochrome c reduction, was significantly lower in
patients on dialysis than in healthy controls. After the replace-
ment of l,25(OH)2D3 the production of 02 by MN reached
values comparable with those observed in controls. In addition,
the capacity of PMNL to generate 02 also showed a slight
improvement, which, however, did not reach a significant level.
Previous studies have shown that peripheral blood MN as
well as peritoneal macrophages (PMØ) from healthy donors
exhibit an augmented PMA-induced H202 and 02 production
after in vitro incubation with 1,25(OH)2D3 [8—11]. Our results
indicate that O generation by MN from patients on chronic
hemodialysis treatment with I ,25(OH)2D3-deficiency is dimin-
ished and can be improved after replacement of the active
hormone. The mechanisms by which l,25(OH)2D3 enhances the
cell's capacity for O2 generation is not well understood.
Martell, Simpson and Taylor [27] showed that 1,25(OH)2D3
stimulates the increase in protein kinase C (PKC) levels in
leukemic promyelocytic (HL-60) cells. It is well known that
PKC is activated by phorbol esters such as PMA and leads to
cellular activation 1 phagocyte oxidative metabolism [28].
Furthermore, Wali et al [291 demonstrated recently that
1 ,25(OH)2D3 stimulates membrane phosphoinositide turnover,
activates PKC and increases cytosolic calcium in rat colonic
epithelium. All these mechanisms are known to be involved in
the activation of the leukocyte respiratory burst [30].
For further evaluation of the oxidative metabolism from
phagocytes, we used two different CL assays. Lucigenin-
enhanced CL was used because its light emission represents an
additional, but more sensitive measure of the 02 production
than the cytochrome c reduction assay [31, 32]. On the other
hand, luminol-enhanced CL was used to detect oxygen metab-
olites arising from myeloperoxidase (MPO) activity. It had been
shown that its light emission is dependent on the presence of
MPO [33]. In accordance with the results obtained in the
cytochrome c reduction assay, the lucigenin-enhanced CL
response of PMA-stimulated MN from dialysis patients was
100
PMNL MN
Fig. 3. Killing of Staphylococcus aureus by polymorphonuclear leuko-
cytes (PMNL) and monocytes (MN) from patients with chronic dialysis
treatment before () and after () replacement therapy with
I,25(OH)2D3 compared to healthy controls (•). Data are mean SD;
* P = 0.011; ** P = 0.019.
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significantly lower than that of healthy controls. After
1 ,25(OH)2D3 therapy the PMA-stimulated monocytes showed a
significant rise in their lucigenin-amplified light emission. In
contrast, the luminol-enhanced CL response of MN from pa-
tients on dialysis were slightly, but not significantly reduced
compared to that of controls. After 1 ,25(OH)2D3 therapy there
was no significant change. This result suggests a normal MPO-
dependent oxidative metabolism in these cells, which is not
influenced by l,25(OH)2D.
The PMNL response in the luminol-amplified assay from
patients on dialysis treatment was also slightly but not signifi-
cantly reduced. After the replacement of l,25(OH)2D3 no
significant changes could be observed.
No significant changes were also observed by the determina-
tion of the phagocytic capability, measured by the uptake of
preopsonized, radiolabeled S. aureus. Both PMNL and MN
showed a normal activity compared to healthy controls, which
was not altered by in vivo replacement of 1 ,25(OH)2D3.
Furthermore, it could be demonstrated that the intracellular
killing of S. aureus by MN from patients on hemodialysis is
significantly diminished compared to healthy controls, and
exhibits a significant improvement after in vivo replacement of
l,25(OH)2D3. In contrast to our results, Venezio et al [16]
described a normal killing capacity of MN both before and after
1,25(OH)2D3 therapy. It is difficult to compare the results of
these authors with ours, because they employed another assay
system and determined the fungicidal capacity by using C.
albicans. However, our findings are in accordance with several
in vitro data describing an enhanced killing capacity of MN as
well as PMØ after in vitro incubation with 1 ,25(OH)2D3 [10, 11,
241. The enhancement of MN's bactericidal capacity most likely
reflects the stimulated oxidative metabolism with an increased
generation of toxic metabolites, such as 02 which could be
observed after 1 ,25(OH)2D3 treatment. In addition, the bacte-
ricidal capacity of PMNL was found to be normal and did not
change after the replacement of 1 ,25(OH)2D3.
Another factor influencing the bacterial killing and superox-
ide production could be the increase of the serum calcium and
phosphate concentration under treatment with 1 ,25(OH)2D3.
The data in the literature are conflicting with regard to the
influence of calcium and phosphate metabolism on phagocyte
functions. Previously, Carozzi et al [101 found a dose dependent
increase of superoxide production and killing capacity after in
vitro treatment of peritoneal macrophages (PMØ) with calcium
concentrations between 0.5 and 3 mrvi in the medium, while
calcium-free and 5 m solutions suppressed these functions.
On the other hand Khan et al [34] reported an inverse correla-
tion between calcium levels, random migration and chemotaxis
of PMNL from patients with primary hyperparathyreoidism.
Doherty et al [351 found no influence of different calcium
concentrations on the random migration of PMNL.
Hallgren et al [36] described an inverse relationship between
serum phosphate levels and phagocytic ability of PMNL,
whereas Cecchin et al [37] found no influence of anorganic
phosphate on the phagocytic and killing activity of peritoneal
PMNL. After 1 ,25(OH)2D3 treatment we found a significant
increase of serum calcium and phosphate levels, but when our
data of superoxide production and killing capacity of MN were
evaluated by regression analysis in relation to the increase of
calcium and phosphate, no significant correlation was found.
However, the increase of calcium concentration in our study
was in a small range (mean 0.24 mM) in comparison to those
concentrations used in the in vitro study of Carozzi et al [101.
This could be the reason that we did not find a correlation
between the serum calcium levels and the increase of MN's
killing capacity and superoxide production.
Previously Doherty et al [35] reported a significant inhibition
of random migration of PMNL by prolonged exposure to PTH
in patients with advanced renal failure. He showed a significant
inverse relationship of random migration with serum level of
PTH. However, we did not observe a significant change in the
functional activity of PMNL, while the PTH level significantly
decreased. Furthermore, we did not find a significant relation-
ship between PTH level and the augmentation of oxidative
metabolism and killing capacity of MN.
It is known that l,25(OH)2D3 also acts on activated T
lymphocytes [25]. Thus, lymphocyte- and/or lymphokine-medi-
ated effects may contribute to the observed changes in mono-
cyte function. It has been previously described that
1 ,25(OH)2D3 is a potent inhibitor of T-cell-proliferation as well
as of interleukin-2 and interferon-y production [38]. Both of
these lymphokines are known to be potent stimulators of
monocyte function. According to these findings one would
expect a suppression rather than an stimulation of monocyte
function under treatment with l,25(OH)2D3. Thus, it seems to
be unlikely that lymphocyte-mediated effects are responsible
for the observed enhancement of monocyte function.
In conclusion, superoxide generation and killing capacity of
monocytes from patients with end-stage renal disease who are
on hemodialysis treatment were diminished and showed a
significant improvement after an in vivo replacement therapy of
1,25-dihydroxyvitamin D3. Thus, the deficiency of 1,25-dihy-
droxyvitamin D3 may be one of the factors contributing to the
increased susceptibility for infections in patients with ESRD on
dialysis treatment. The precise mechanisms modulating the
enhancement of monocyte function by 1 ,25-dihydroxyvitamin
D3 are currently not yet understood and need further investi-
gation.
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